Get access

Update on extracorporeal photopheresis in heart and lung transplantation

Authors

  • Marisa B. Marques,

    Corresponding author
    1. Department of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, Birmingham, Alabama
    • Department of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, 619 19th Street South, West Pavilion P230G, Birmingham, AL 35244
    Search for more papers by this author
  • Joseph Schwartz

    1. Transfusion Medicine and Cellular Therapy Section, Department of Pathology and Cell Biology, Columbia University Medical Center, New York City, New York
    Search for more papers by this author

  • From the Proceedings of the 31st Annual Meeting of the American Society for Apheresis, May 26–29, 2010, New Orleans, LA.

Abstract

Transplant rejection of solid organs remains a threat to thousands of patients despite modern immunosuppressive regimens. The currently available drugs are associated with severe complications such as hypertension, diabetes mellitus, renal failure, risk of infections, and malignancies among many others and, often enough, still allow episodes of rejection. New and less-toxic immunologic measures are desperately needed to accomplish the desired tolerance to the transplant without the undesirable side effects. Extracorporeal photopheresis (ECP) has been shown to benefit especially patients with cardiac transplants, but also those who received lung allografts. ECP likely modulates the recipient's antigen-specific immune responses and inflammation in transplantation by in vivo generation of apoptotic leukocytes. This review will highlight the need for ECP, how it is thought to act, and the published evidence for its role in cardiac and pulmonary transplantation. J. Clin. Apheresis, 2011. © 2010 Wiley-Liss, Inc.

Get access to the full text of this article

Ancillary